Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.76 USD
+0.06 (2.22%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $2.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Poseida Therapeutics, Inc. (PSTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.00 | $20.00 | $10.00 | 418.52% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Poseida Therapeutics, Inc. comes to $14.00. The forecasts range from a low of $10.00 to a high of $20.00. The average price target represents an increase of 418.52% from the last closing price of $2.70.
Analyst Price Targets (3 )
Broker Rating
Poseida Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PSTX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/6/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
8/5/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
7/25/2024 | H.C. Wainwright & Co. | Arthur He | Strong Buy | Strong Buy |
3/1/2024 | Cantor Fitzgerald & Co | Jennifer Kim | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Justin R Zelin | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $14.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 253 |
Current Quarter EPS Est: | -0.42 |